Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. breast cancer cooperative group

A. T. van Oosterom, H. T. Mouridsen, J. Wildiers, R. Paridaens, G. Cocconi, N. Rotmensz, R. Sylvester

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Sixty-four patients with advanced progressive breast cancer resistant to conventional treatments were entered into the present study. They were randomized to receive either Carminomycin (CMM) 20 mg/m2 or Doxorubicin (DOX) 75 mg/m2, both drugs being administered by i.v. bolus every 3 weeks until progression of the disease. Five patients were not eligible and response could not be evaluated in another eight patients. Three patients had only one course due to disease-related early death. Among twenty-seven evaluable patients who received at least two courses of DOX one complete response and seven partial responses were observed for an overall response rate of 30%. CMM showed significantly lower (P = 0.04) antitumor activity with only one partial response (4%) among the 24 patients who received at least two courses of therapy. Median duration of response dating from the start of chemotherapy was 46 weeks on DOX (range 18-102+) and 30 weeks for the single partial response on CMM. Although the median time to progression for all patients receiving CMM (9 weeks) was significantly shorter (P = 0.04) than for those receiving DOX (30 weeks), patients on DOX had only a marginally longer duration of survival (P = .28) than those initially treated with CMM. Myelotoxicity was more severe in the GMM treated group than in the DOX group. Other toxicities such as alopecia, nausea and vomiting were slightly more severe in the DOX treated group. On the basis of this and other similar randomized studies, CMM cannot be recommended for further application in the treatment of advanced breast cancer.

Original languageEnglish
Pages (from-to)601-605
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Volume22
Issue number5
DOIs
Publication statusPublished - 1986

Fingerprint

Carubicin
Doxorubicin
Breast Neoplasms
Alopecia
Nausea
Vomiting
Disease Progression
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. breast cancer cooperative group. / van Oosterom, A. T.; Mouridsen, H. T.; Wildiers, J.; Paridaens, R.; Cocconi, G.; Rotmensz, N.; Sylvester, R.

In: European Journal of Cancer and Clinical Oncology, Vol. 22, No. 5, 1986, p. 601-605.

Research output: Contribution to journalArticle

van Oosterom, A. T. ; Mouridsen, H. T. ; Wildiers, J. ; Paridaens, R. ; Cocconi, G. ; Rotmensz, N. ; Sylvester, R. / Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. breast cancer cooperative group. In: European Journal of Cancer and Clinical Oncology. 1986 ; Vol. 22, No. 5. pp. 601-605.
@article{fe9c3b37d14b44c188b285b011cf6b95,
title = "Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. breast cancer cooperative group",
abstract = "Sixty-four patients with advanced progressive breast cancer resistant to conventional treatments were entered into the present study. They were randomized to receive either Carminomycin (CMM) 20 mg/m2 or Doxorubicin (DOX) 75 mg/m2, both drugs being administered by i.v. bolus every 3 weeks until progression of the disease. Five patients were not eligible and response could not be evaluated in another eight patients. Three patients had only one course due to disease-related early death. Among twenty-seven evaluable patients who received at least two courses of DOX one complete response and seven partial responses were observed for an overall response rate of 30{\%}. CMM showed significantly lower (P = 0.04) antitumor activity with only one partial response (4{\%}) among the 24 patients who received at least two courses of therapy. Median duration of response dating from the start of chemotherapy was 46 weeks on DOX (range 18-102+) and 30 weeks for the single partial response on CMM. Although the median time to progression for all patients receiving CMM (9 weeks) was significantly shorter (P = 0.04) than for those receiving DOX (30 weeks), patients on DOX had only a marginally longer duration of survival (P = .28) than those initially treated with CMM. Myelotoxicity was more severe in the GMM treated group than in the DOX group. Other toxicities such as alopecia, nausea and vomiting were slightly more severe in the DOX treated group. On the basis of this and other similar randomized studies, CMM cannot be recommended for further application in the treatment of advanced breast cancer.",
author = "{van Oosterom}, {A. T.} and Mouridsen, {H. T.} and J. Wildiers and R. Paridaens and G. Cocconi and N. Rotmensz and R. Sylvester",
year = "1986",
doi = "10.1016/0277-5379(86)90050-7",
language = "English",
volume = "22",
pages = "601--605",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "5",

}

TY - JOUR

T1 - Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. breast cancer cooperative group

AU - van Oosterom, A. T.

AU - Mouridsen, H. T.

AU - Wildiers, J.

AU - Paridaens, R.

AU - Cocconi, G.

AU - Rotmensz, N.

AU - Sylvester, R.

PY - 1986

Y1 - 1986

N2 - Sixty-four patients with advanced progressive breast cancer resistant to conventional treatments were entered into the present study. They were randomized to receive either Carminomycin (CMM) 20 mg/m2 or Doxorubicin (DOX) 75 mg/m2, both drugs being administered by i.v. bolus every 3 weeks until progression of the disease. Five patients were not eligible and response could not be evaluated in another eight patients. Three patients had only one course due to disease-related early death. Among twenty-seven evaluable patients who received at least two courses of DOX one complete response and seven partial responses were observed for an overall response rate of 30%. CMM showed significantly lower (P = 0.04) antitumor activity with only one partial response (4%) among the 24 patients who received at least two courses of therapy. Median duration of response dating from the start of chemotherapy was 46 weeks on DOX (range 18-102+) and 30 weeks for the single partial response on CMM. Although the median time to progression for all patients receiving CMM (9 weeks) was significantly shorter (P = 0.04) than for those receiving DOX (30 weeks), patients on DOX had only a marginally longer duration of survival (P = .28) than those initially treated with CMM. Myelotoxicity was more severe in the GMM treated group than in the DOX group. Other toxicities such as alopecia, nausea and vomiting were slightly more severe in the DOX treated group. On the basis of this and other similar randomized studies, CMM cannot be recommended for further application in the treatment of advanced breast cancer.

AB - Sixty-four patients with advanced progressive breast cancer resistant to conventional treatments were entered into the present study. They were randomized to receive either Carminomycin (CMM) 20 mg/m2 or Doxorubicin (DOX) 75 mg/m2, both drugs being administered by i.v. bolus every 3 weeks until progression of the disease. Five patients were not eligible and response could not be evaluated in another eight patients. Three patients had only one course due to disease-related early death. Among twenty-seven evaluable patients who received at least two courses of DOX one complete response and seven partial responses were observed for an overall response rate of 30%. CMM showed significantly lower (P = 0.04) antitumor activity with only one partial response (4%) among the 24 patients who received at least two courses of therapy. Median duration of response dating from the start of chemotherapy was 46 weeks on DOX (range 18-102+) and 30 weeks for the single partial response on CMM. Although the median time to progression for all patients receiving CMM (9 weeks) was significantly shorter (P = 0.04) than for those receiving DOX (30 weeks), patients on DOX had only a marginally longer duration of survival (P = .28) than those initially treated with CMM. Myelotoxicity was more severe in the GMM treated group than in the DOX group. Other toxicities such as alopecia, nausea and vomiting were slightly more severe in the DOX treated group. On the basis of this and other similar randomized studies, CMM cannot be recommended for further application in the treatment of advanced breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0022632213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022632213&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(86)90050-7

DO - 10.1016/0277-5379(86)90050-7

M3 - Article

C2 - 3770031

AN - SCOPUS:0022632213

VL - 22

SP - 601

EP - 605

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -